

Corrigendum

Corrigendum to Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association [Journal of Clinical Lipidology Volume 13, Issue 3, May–June 2019, Pages 374–392]

Don P. Wilson, MD*, Terry A. Jacobson, MD, Peter H. Jones, MD, Marlys L. Koschinsky, PhD, Catherine J. McNeal, MD, PhD, Børge G. Nordestgaard, MD, DMSc, Carl E. Orringer, MD

Department of Pediatric Endocrinology and Diabetes, Cook Children's Medical Center, Fort Worth, TX, USA (Dr Wilson); Department of Medicine, Lipid Clinic and Cardiovascular Risk Reduction Program, Emory University, Atlanta, GA, USA (Dr Jacobson); Department of Medicine, Baylor College of Medicine, Houston, TX, USA (Dr Jones); Robarts Research Institute, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada (Dr Koschinsky); Division of Cardiology, Department of Internal Medicine, Baylor Scott & White Health, Temple, TX, USA (Dr McNeal); Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark (Dr Nordestgaard); Division of Cardiology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA (Dr Orringer)

The authors regret that the printed version of the above article contained a number of errors. The correct and final

version follows. The authors would like to apologise for any inconvenience caused.

* Corresponding author at: Lipoprotein(a) Scientific Statement Committee, National Lipid Association, Pediatric Endocrinology and Diabetes, Cook Children's, Medical Center, 1500 Cooper Street, 2nd Floor, Fort Worth, TX, 76104, USA.

E-mail address: don.wilson@cookchildrens.org (D.P. Wilson).